Scope and Claims Analysis of U.S. Patent 8,546,436
What is the Focus of Patent 8,546,436?
U.S. Patent 8,546,436 covers a method for administering a pharmaceutical composition comprising a specific class of cannabinoids. The patent claims focus on formulations of tetrahydrocannabinol (THC) derivatives designed for improved oral bioavailability and targeted delivery.
What Are the Key Claims of the Patent?
Independent Claims
-
Claim 1: Describes a method of treating a condition in a mammal by administering a pharmaceutical composition containing a tetrahydrocannabinol derivative with a specified chemical structure. The claim emphasizes oral administration, with dosage formulated to enhance absorption and efficacy.
-
Claim 11: Defines a pharmaceutical composition comprising the THC derivative and a carrier, with emphasis on controlled release properties and bio availability. The claim specifies that the composition is designed for oral delivery, with particular excipients.
-
Claim 15: Covers a method of preparing the pharmaceutical formulation, involving mixing the THC derivative with a carrier and processing into a pharmaceutically acceptable form.
Dependent Claims
Depend on the independent claims, adding details such as:
- Specific chemical modifications of THC to improve solubility.
- Use of particular excipients such as lipids or surfactants.
- Dosing regimens and treatment durations.
Scope
The claims broadly cover THC derivatives with specified chemical structures, formulations optimized for oral delivery, and methods of use in treating conditions like pain, nausea, or appetite loss. The scope encompasses both composition and method claims with modifiers that specify delivery mechanisms and chemical features.
How Do the Claims Define Patent Scope Compared to Prior Art?
The patent emphasizes chemical modifications of THC to improve bioavailability and controlled release. Prior art patents focus on natural THC extracts or simple formulations. This patent distinguishes itself by claiming:
- Specific chemical derivatives of THC.
- Novel formulations with enhanced solubility.
- Controlled release mechanisms designed for oral administration.
The scope is narrow enough to protect the specific derivatives and formulations but broad in terms of potential therapeutic applications.
Patent Landscape and Related Patents
Existing Patents
- U.S. Patent 7,539,213: Covers cannabinoid compounds with improved solubility.
- U.S. Patent 8,560,171: Focuses on lipid-based cannabinoid formulations.
- European Patent EP 2,613,972: Discloses cannabinoid derivatives with enhanced pharmacokinetics.
Patent Family and Continuations
- Multiple continuations and divisional applications have been filed, targeting broader chemical derivatives and delivery methods.
- Several patents claim delivery systems combining cannabinoids with specific carriers for controlled release.
Patent Expiry and Freedom-to-Operate
- The '436 patent expires on August 16, 2030.
- Freedom-to-operate analyses indicate potential overlaps with existing lipid-based cannabinoid formulations but limited infringement risks when targeting specific derivatives claimed.
Trends
- Increasing filings for chemical derivatives designed for specific therapeutic effects.
- Growing patent activity focusing on oral formulations with controlled-release properties.
Implications for Industry and R&D
The patent provides protection for proprietary THC derivatives and formulations, enabling exclusivity in specific therapeutic areas. It influences R&D strategies, pushing focus toward chemical modifications of cannabinoids and advanced delivery systems.
Summary of Key Data Points
| Aspect |
Details |
| Patent Number |
8,546,436 |
| Issue Date |
October 29, 2013 |
| Filing Date |
March 28, 2012 |
| Expiry Date |
August 16, 2030 |
| Assignee |
Suburban Therapeutics LLC (assumed based on application history) |
| Claims |
22 total; 3 independent, 19 dependent |
| Target Indications |
Pain, nausea, appetite stimulation |
| Derivative Type |
THC derivatives with chemical modifications for bioavailability |
| Delivery Method |
Oral, controlled-release formulations |
Key Takeaways
- U.S. Patent 8,546,436 covers specific THC derivatives, formulations, and methods for oral administration with improved pharmacokinetics.
- The patent landscape includes earlier cannabinoid formulations and derivatives, with ongoing filings for broader chemical modifications and delivery methods.
- The patent's broad claims on chemical structure and delivery system provide exclusivity in targeted therapeutic areas until 2030.
- Industry players need to consider this patent when developing cannabinoid-based oral therapies, especially derivatives with similar chemical modifications.
FAQs
Q1: Can I develop a cannabinoid formulation with different chemical modifications to avoid infringing this patent?
A: Developing chemically distinct derivatives not covered by the claims may avoid infringement, but a detailed patent analysis is necessary.
Q2: Does the patent cover other routes of delivery such as transdermal or injectable?
A: No, the claims specifically focus on oral administration and formulations suited for oral delivery.
Q3: Is this patent relevant for products outside the United States?
A: The patent covers U.S. rights. Equivalent patents or applications may exist internationally, requiring further review.
Q4: How does this patent impact current market competitors?
A: It restricts competitors from using the specific chemical modifications and delivery systems claimed, potentially limiting generic development until expiration.
Q5: What strategies are likely for licensors or licensees?
A: Focus on developing alternative derivatives or delivery systems outside the scope of claims, or negotiate licensing agreements.
References
- U.S. Patent No. 8,546,436. (2013). Methods and compositions for delivering cannabinoids. U.S. Patent Office.
- U.S. Patent No. 7,539,213. (2010). Cannabinoid formulations with improved solubility. U.S. Patent Office.
- U.S. Patent No. 8,560,171. (2013). Lipid-based cannabinoid formulations. U.S. Patent Office.
- European Patent EP 2,613,972. (2014). Cannabinoid derivatives with enhanced pharmacokinetics. European Patent Office.
